Literature DB >> 35262376

Implementation of Safe Supply Alternatives During Intersecting COVID-19 and Overdose Health Emergencies in British Columbia, Canada, 2021.

Ryan McNeil1, Taylor Fleming1, Samara Mayer1, Allison Barker1, Manal Mansoor1, Alex Betsos1, Tamar Austin1, Sylvia Parusel1, Andrew Ivsins1, Jade Boyd1.   

Abstract

Objectives. To explore the implementation and effectiveness of the British Columbia, Canada, risk mitigation guidelines among people who use drugs, focusing on how experiences with the illicit drug supply shaped motivations to seek prescription alternatives and the subsequent impacts on overdose vulnerability. Methods. From February to July 2021, we conducted qualitative interviews with 40 people who use drugs in British Columbia, Canada, and who accessed prescription opioids or stimulants under the risk mitigation guidelines. Results. COVID-19 disrupted British Columbia's illicit drug market. Concerns about overdose because of drug supply changes, and deepening socioeconomic marginalization, motivated participants to access no-cost prescription alternatives. Reliable access to prescription alternatives addressed overdose vulnerability by reducing engagement with the illicit drug market while allowing greater agency over drug use. Because prescriptions were primarily intended to manage withdrawal, participants supplemented with illicit drugs to experience enjoyment and manage pain. Conclusions. Providing prescription alternatives to illicit drugs is a critical harm reduction approach that reduces exposure to an increasingly toxic drug supply, yet further optimizations are needed. (Am J Public Health. 2022;112(S2):S151-S158. https://doi.org/10.2105/AJPH.2021.306692).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35262376      PMCID: PMC8965179          DOI: 10.2105/AJPH.2021.306692

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  25 in total

1.  The social structural production of HIV risk among injecting drug users.

Authors:  Tim Rhodes; Merrill Singer; Philippe Bourgois; Samuel R Friedman; Steffanie A Strathdee
Journal:  Soc Sci Med       Date:  2005-03-19       Impact factor: 4.634

2.  Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings.

Authors:  Lianping Ti; Samuel Tobias; Nazlee Maghsoudi; M-J Milloy; Karen McDonald; Aaron Shapiro; Daniel Beriault; Cristiana Stefan; Mark Lysyshyn; Daniel Werb
Journal:  Drug Alcohol Rev       Date:  2020-12-22

3.  An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program using point-of-care and confirmatory methods.

Authors:  Matthew K Laing; Lianping Ti; Allison Marmel; Samuel Tobias; Aaron M Shapiro; Richard Laing; Mark Lysyshyn; M Eugenia Socías
Journal:  Int J Drug Policy       Date:  2021-02-22

4.  COVID-19 and the Drug Overdose Crisis: Uncovering the Deadliest Months in the United States, January‒July 2020.

Authors:  Joseph Friedman; Samir Akre
Journal:  Am J Public Health       Date:  2021-04-15       Impact factor: 11.561

5.  Tackling the overdose crisis: The role of safe supply.

Authors:  Andrew Ivsins; Jade Boyd; Leo Beletsky; Ryan McNeil
Journal:  Int J Drug Policy       Date:  2020-05-01

6.  Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study.

Authors:  Andrew Ivsins; Jade Boyd; Samara Mayer; Alexandra Collins; Christy Sutherland; Thomas Kerr; Ryan McNeil
Journal:  Drug Alcohol Depend       Date:  2020-09-15       Impact factor: 4.492

Review 7.  Stimulant safe supply: a potential opportunity to respond to the overdose epidemic.

Authors:  Taylor Fleming; Allison Barker; Andrew Ivsins; Sheila Vakharia; Ryan McNeil
Journal:  Harm Reduct J       Date:  2020-01-10

8.  Notes from the Field: Opioid Overdose Deaths Before, During, and After an 11-Week COVID-19 Stay-at-Home Order - Cook County, Illinois, January 1, 2018-October 6, 2020.

Authors:  Maryann Mason; Sarah B Welch; Ponni Arunkumar; Lori Ann Post; Joseph M Feinglass
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-03-12       Impact factor: 17.586

9.  Trends in Drug Overdose Mortality in Ohio During the First 7 Months of the COVID-19 Pandemic.

Authors:  Janet M Currie; Molly K Schnell; Hannes Schwandt; Jonathan Zhang
Journal:  JAMA Netw Open       Date:  2021-04-01

10.  Impact of COVID-19 Pandemic on Drug Overdoses in Indianapolis.

Authors:  Nancy Glober; George Mohler; Philip Huynh; Tom Arkins; Dan O'Donnell; Jeremy Carter; Brad Ray
Journal:  J Urban Health       Date:  2020-10-01       Impact factor: 3.671

View more
  4 in total

1.  Self-reported impacts of the COVID-19 pandemic among people who use drugs: a rapid assessment study in Montreal, Canada.

Authors:  Nanor Minoyan; Stine Bordier Høj; Camille Zolopa; Dragos Vlad; Julie Bruneau; Sarah Larney
Journal:  Harm Reduct J       Date:  2022-04-18

2.  Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness.

Authors:  Thomas D Brothers; Malcolm Leaman; Matthew Bonn; Dan Lewer; Jacqueline Atkinson; John Fraser; Amy Gillis; Michael Gniewek; Leisha Hawker; Heather Hayman; Peter Jorna; David Martell; Tiffany O'Donnell; Helen Rivers-Bowerman; Leah Genge
Journal:  Drug Alcohol Depend       Date:  2022-04-07       Impact factor: 4.852

3.  Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario.

Authors:  Tara Gomes; Gillian Kolla; Daniel McCormack; Andrea Sereda; Sophie Kitchen; Tony Antoniou
Journal:  CMAJ       Date:  2022-09-19       Impact factor: 16.859

4.  Moving towards a continuum of safer supply options for people who use drugs: A qualitative study exploring national perspectives on safer supply among professional stakeholders in Canada.

Authors:  Annie Foreman-Mackey; Bernie Pauly; Andrew Ivsins; Karen Urbanoski; Manal Mansoor; Geoff Bardwell
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-10-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.